ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
28 February 2023 - 01:20AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for the treatment of inflammatory and renal diseases with
high unmet medical needs, announced today that Stephen C. Glover,
Co-Founder, Chairman, Chief Executive Officer, and President will
participate in a fireside chat at the 35th Annual Roth Conference
scheduled for March 12-14, 2023 to be held at The Ritz Carlton,
Laguna Niguel in Dana Point, California.
Details regarding ZyVersa’s fireside chat are as follows:
Event: 35th Annual Roth
Conference
Date: Tuesday, March 14,
2023
Time: 2:00 PM
PST
Location: Healthcare, Salon 5
- The Ritz Carlton, Dana Point, California
“We look forward to discussing ZyVersa’s two platform
technologies and highlighting our expected key milestones with
investors attending the Roth Conference,” stated Mr. Glover.
“ZyVersa is currently advancing two product candidates, Cholesterol
Efflux Mediator™ VAR 200 in development to ameliorate renal
lipid accumulation that damages the kidneys' filtration system, and
inflammasome ASC inhibitor IC 100 which blocks initiation and
perpetuation of damaging inflammation associated with numerous
inflammatory diseases.”
To learn more about ZyVersa and its differentiated product
pipeline, please request a one-on-one meeting with Mr. Glover
through the conference portal.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. ZyVersa’s focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. The
company’s development pipeline includes phase 2a-ready Cholesterol
Efflux Mediator™ VAR 200 for treatment of rare kidney disease,
focal segmental glomerulosclerosis (FSGS). Other potential
indications for VAR 200 include Alport syndrome and diabetic kidney
disease. ZyVersa’s development pipeline also includes novel
inflammasome ASC inhibitor IC 100 to control damaging inflammation
associated with a multitude of inflammatory diseases. IC 100 has
potential to treat numerous CNS and other inflammatory diseases.
For more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Oct 2023 to Nov 2023
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Nov 2022 to Nov 2023